Compass Therapeutics faced a setback as their drug tovecimig did not show an overall survival benefit in treating biliary tract cancer. Despite FDA advice to conduct a new trial focused on survival, the company plans to proceed with a Biologics License Application (BLA) submission. Compass has financial resources extending into 2028, but any delays or regulatory challenges could force them to raise capital under less favorable conditions. While market sentiment is negative, some see a high-risk buying opportunity if investors remain disciplined.
Compass Therapeutics faces a critical moment as it plans a Biologics License Application despite recent trial setbacks. For readers following the health sector, here is Pluang's market snapshot as of Sep 23, 2026 20:52 WIB: out of 100 priced health-sector US stocks, 35 rose and 64 fell. Notable movers include ASND at USD 233.46 (-1.73%), XRAY at USD 9.78 (-1.71%), and HRTX at USD 0.29 (-1.67%) with a strong buy order activity of 83%.
Oppenheimer lowered Nike's price target to $52 from a higher level, reflecting concerns over falling sales and macroeconomic challenges. Despite Nike's stock trading near its 52-week low around $35.35, the new target implies a potential 44.85% upside...
Stifel Financial upgraded Microsoft from Hold to Buy, raising its price target to $575 due to strong growth prospects in Azure cloud services and Microsoft 365 Copilot. The analyst highlighted Azure's 43% year-over-year revenue growth and over 30 mil...
Apple Inc. remains a major institutional holding with a market cap near $5 trillion as of September 2026. Recent filings show Robinhood Asset Management increased its Apple shares from 97,500 to 122,289 between March and June, while Westpac Banking C...
Paychex, Inc. reported strong first-quarter results with an adjusted EPS of $1.34, beating estimates, and total revenue of $1.63 billion, a 6% increase year-over-year. Growth was led by a 12% rise in the Professional Employer Organization (PEO) and I...
RBC Capital assigned Fastly a "Sector Perform" rating, signaling a neutral investment outlook. Fastly aims to grow its revenue to $1.1-$1.3 billion by 2029, driven by steady operational improvements and a $22 billion market opportunity. The company i...
